Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

Income Statement

Follow revenue through to earnings.

Revenue

$216.10M

FY 2025 · Annual

+8.7% YoY

Operating Income

-$151.17M

FY 2025 · Annual

Net Income

-$220.47M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue268.68M254.38M192.64M198.77M216.11M
Cost of Revenue25.63M24.28M14.8M11.31M13.04M
Gross Profit243.05M230.1M177.84M187.46M203.06M
Gross Margin90.5%90.5%92.3%94.3%94.0%
Research & Development75.36M85.77M76.82M74.43M109.27M
Selling, General & Admin124.05M136.49M112.88M146.41M237.95M
Operating Expenses200.89M223.77M191.8M228.12M354.23M
Depreciation & Amortization2.84M2.73M3.01M8.13M11.92M
EBITDA45.21M14.03M9.35M(14.79M)(126.73M)
EBITDA Margin16.8%5.5%4.9%-7.4%-58.6%
Operating Income42.17M6.33M(13.95M)(40.66M)(151.17M)
Operating Margin15.7%2.5%-7.2%-20.5%-70.0%
Interest Income199K0000
Interest Expense00000
Other Income / Expenses199K4.97M20.29M17.74M12.52M
Income Before Tax42.36M11.3M6.34M(22.92M)(138.65M)
Pre-Tax Margin15.8%4.4%3.3%-11.5%-64.2%
Income Tax Expense9.21M5.03M3.83M(4.02M)81.83M
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Net Margin12.3%2.5%1.3%-9.5%-102.0%
EPS (Basic)0.600.110.04(0.32)(3.74)
EPS (Diluted)0.580.110.04(0.32)(3.74)
Weighted Avg Shares55.55M56.46M57.38M58.15M58.93M
Weighted Avg Shares (Diluted)56.92M56.98M57.56M58.15M58.93M

VNDA Earnings Waterfall · TTM

NASDAQ:VNDA · Revenue to Net Income

Key Ratios

EPS$-4.05
Gross Margin92.4%
Net Margin-108.1%
P/E Ratio-2.2
P/S Ratio6.9

Analysis

$217.8M of revenue converted into -$239.5M of net income for the selected period. Gross margin is 92.4% and net margin is -108.1%, showing how much revenue survives after costs and taxes. EPS is $-4.05, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipNov 5, 2026
10-QQuarterly reportOct 29, 2026
8-KCurrent reportOct 28, 2026

How much revenue does VNDA generate?

Vanda Pharmaceuticals Inc. (VNDA) reported $216.10M of revenue in fiscal 2025.

Is VNDA profitable?

Vanda Pharmaceuticals Inc. (VNDA) reported -$220.47M of net income, with a net margin of -102.0%.